|
|
|
|
November 1, 2010--The Deal Pipeline's senior writer Cecile Kohrs Lindell today reported that Spanish blood plasma company Grifols SA's proposed $4 billion acquisition of North Carolina based Talecris Biotherapeutics Holdings Corp. appears increasingly likely to be challenged by the U.S. Federal Trade Commission.
A Washington antitrust lawyer familiar with the FTC's investigation told The Deal Pipeline that preparations for an FTC lawsuit seeking to block the deal are under way.
Bloomberg News credited The Deal Pipeline with this scoop, along with North Carolina based media outlets The News & Observer and Triangle Business Journal.
